The FDA IND clearance for NUC-7738 is a significant de-risking catalyst that opens a U.S. regulatory pathway, and the cash runway into 2029 removes near-term dilution risk. Traders should watch for final Phase 2 data in melanoma later this year, which could be a major value inflection point. The massive option grant (3.85B shares) signals heavy dilution potential if exercised, but the low exercise price (£0.0004) and current share price context make this a long-term overhang rather than an immediate concern.
Price Chart
Executive Summary
NuCana reported Q1 2026 results with a net loss of £3.9M, wider than the £2.5M loss in Q1 2025, driven by increased R&D spend (£3.2M vs £1.7M) and higher share-based compensation. The company highlighted FDA IND clearance for NUC-7738 in April 2026, enabling U.S. clinical trials, and expects final Phase 2 data for NUC-7738 in melanoma later this year. Cash of £21.5M is expected to fund operations into 2029, but the company remains pre-revenue with no approved products.
Key Facts
- Net loss of £3.9M for Q1 2026 vs £2.5M in Q1 2025
- Cash and cash equivalents of £21.5M as of March 31, 2026, expected to fund operations into 2029
- FDA cleared IND for NUC-7738 in April 2026, enabling U.S. clinical trials
- Final Phase 2 data from NuTide:701 study of NUC-7738 in melanoma expected in 2026
- 3.851 billion share options granted in Q1 2026 under the 2020 LTIP
- No revenue generated; accumulated deficit of £251.2M
Financial Impact
Net loss increased by £1.4M YoY; cash burn of £3.2M in operating activities; cash runway extended into 2029
Risk Factors
- Pre-revenue clinical-stage company with no approved products and history of losses
- Heavy share-based compensation and massive option grants create future dilution risk
- Clinical trial failure or regulatory setback for NUC-7738 or NUC-3373
- Reliance on additional capital beyond current cash runway if development plans expand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-224224 |
| Document: d96757dex993.htm | 0001193125-26-224224 |
| Document: d96757dex992.htm | 0001193125-26-224224 |
| Document: d96757d6k.htm | 0001193125-26-224224 |
| Document: 0001193125-26-224224-index-headers.html | 0001193125-26-224224 |
| Document: 0001193125-26-224224-index.html | 0001193125-26-224224 |
| Document: 0001193125-26-224224.txt | 0001193125-26-224224 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $1.35 | awaiting T+60 | — | $1.10 (−18.52%) |
Jun 8, 2026 20w ago | 6-K | $2.05 $1.38 | ▼ −32.68% | ▼ −35.73% | $1.10 (−46.34%) |
Jun 1, 2026 21w ago | 6-K | $2.17 $1.47 | ▼ −32.26% | ▼ −33.49% | $1.10 (−49.31%) |
May 14, 2026 23w ago | 6-K | $2.18 $1.44 | ▼ −33.95% | ▼ −38.46% | $1.10 (−49.54%) |
May 6, 2026 24w ago | 6-K | $2.09 $1.35 | ▲ +35.41% | ▲ +39.24% | $1.10 (+47.37%) |
Mar 19, 2026 31w ago | Press Release | $1.65 $1.92 | ▲ +16.36% | ▲ +1.94% | $1.10 (−33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers